549 related articles for article (PubMed ID: 34975912)
41. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
42. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
43. Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis.
Ash SL; Orha R; Mole H; Dinesh-Kumar M; Lee SP; Turrell FK; Isacke CM
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38413223
[TBL] [Abstract][Full Text] [Related]
44. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
[TBL] [Abstract][Full Text] [Related]
45. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
Rogosic S; Ghorashian S
Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
[TBL] [Abstract][Full Text] [Related]
46. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
47. A novel chimeric antigen receptor redirecting T-cell specificity towards CD26
Zhou S; Li W; Xiao Y; Zhu X; Zhong Z; Li Q; Cheng F; Zou P; You Y; Zhu X
Leukemia; 2021 Jan; 35(1):119-129. PubMed ID: 32317776
[TBL] [Abstract][Full Text] [Related]
48. CAR Cells beyond Classical CAR T Cells: Functional Properties and Prospects of Application.
Minina EP; Dianov DV; Sheetikov SA; Bogolyubova AV
Biochemistry (Mosc); 2024 May; 89(5):765-783. PubMed ID: 38880641
[TBL] [Abstract][Full Text] [Related]
49. Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors.
Tang X; Li Y; Ma J; Wang X; Zhao W; Hossain MA; Yang Y
Cancer Lett; 2020 Sep; 487():1-9. PubMed ID: 32454143
[TBL] [Abstract][Full Text] [Related]
50. Chimeric antigen receptor T cells therapy in solid tumors.
Rababah F; Alabduh T; Awawdeh A; Shatnawi T; Al-Shdaifat M; Ibdah E; Shatnawi S; AbuZetun Y; Helaly AM; Ghorab DS
Clin Transl Oncol; 2023 Aug; 25(8):2279-2296. PubMed ID: 36853399
[TBL] [Abstract][Full Text] [Related]
51. Single-cell RNA-Seq reveals the potential risk of anti-mesothelin CAR T Cell therapy toxicity to different organs in humans.
Wen L; Huang Y; Peng L; Zhao K; Sun Y; Lin Z; Chen Y; Li Z; Qian Q; Tong F; Zhang R; Dong X
Front Immunol; 2022; 13():807915. PubMed ID: 36059490
[TBL] [Abstract][Full Text] [Related]
52. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
53. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
[TBL] [Abstract][Full Text] [Related]
54. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
55. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
56. Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia.
Ceppi F; Gardner RA
Cancer J; 2019; 25(3):191-198. PubMed ID: 31135526
[TBL] [Abstract][Full Text] [Related]
57. Designed improvement to T-cell immunotherapy by multidimensional single cell profiling.
Bandey IN; Adolacion JRT; Romain G; Paniagua MM; An X; Saeedi A; Liadi I; You Z; Rajanayake RB; Hwu P; Singh H; Cooper LJ; Varadarajan N
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722906
[TBL] [Abstract][Full Text] [Related]
58. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
[TBL] [Abstract][Full Text] [Related]
59. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.
Li Y; Hu Z; Li Y; Wu X
Front Immunol; 2024; 15():1409021. PubMed ID: 38751430
[TBL] [Abstract][Full Text] [Related]
60. Immunobiology of chimeric antigen receptor T cells and novel designs.
Walsh Z; Yang Y; Kohler ME
Immunol Rev; 2019 Jul; 290(1):100-113. PubMed ID: 31355496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]